Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Denali Capital Acquisition Corp
Deal Size : Undisclosed
Deal Type : Merger
Semnur to go Public via SPAC Merger with Denali Capital in $2.5 bln Deal
Details : Semnur’s lead program, Semdexa (dexamethasone sodium phosphate), is the first non-opioid novel injectable corticosteroid gel formulation for moderate to severe chronic radicular sciatica.
Product Name : Semdexa
Product Type : Steroid
Upfront Cash : Undisclosed
March 09, 2024
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Denali Capital Acquisition Corp
Deal Size : Undisclosed
Deal Type : Merger
A Research Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
August 03, 2018
Reset All
